0000899243-22-036298.txt : 20221117 0000899243-22-036298.hdr.sgml : 20221117 20221117210922 ACCESSION NUMBER: 0000899243-22-036298 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221116 FILED AS OF DATE: 20221117 DATE AS OF CHANGE: 20221117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Goater Jeff CENTRAL INDEX KEY: 0001656435 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 221400360 MAIL ADDRESS: STREET 1: C/O SURFACE ONCOLOGY, INC. STREET 2: 50 HAMPSHIRE STREET, 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-245-0399 MAIL ADDRESS: STREET 1: 65 HAYDEN AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-16 1 0001664106 LogicBio Therapeutics, Inc. LOGC 0001656435 Goater Jeff C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVENUE, FLOOR 2 LEXINGTON MA 02421 1 0 0 0 Stock Option (right to buy) 0.38 2022-11-16 4 D 0 12500 D 2032-06-17 Common Stock 12500 0 D The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc. (the "Company"), subject to the Reporting Person's continued service with the Company on the vesting date. Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. /s/ Frederic Chereau, as Attorney-in-Fact 2022-11-17